Entering text into the input field will update the search result below

RVXCF Resverlogix Corp.
Stock Price & Overview

$0.050.0002 (+0.42%)1:41 PM 12/06/23
Pink Current Info | $USD | Market Close

Charts

FFO (FWD)
PE
Div Rate (TTM)
Yield (TTM)
Short Interest
Market Cap
Volume
Prev. Close

Quant Ranking

People Also Follow

Company Profile

Resverlogix Corp. logo
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company was founded in 2001 and is headquartered in Calgary, Canada.
Employees
-
Founded
2001
Address
  • 4820 Richard Road SW
  • Suite 300
  • Calgary, AB, T3E 6L1
  • Canada
Phone Number
403-254-9252
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.